SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Codexis, Inc. – ‘10-Q’ for 9/30/13 – ‘EX-10.2’

On:  Tuesday, 11/12/13, at 4:56pm ET   ·   For:  9/30/13   ·   Accession #:  1200375-13-11   ·   File #:  1-34705

Previous ‘10-Q’:  ‘10-Q’ on 8/9/13 for 6/30/13   ·   Next:  ‘10-Q’ on 5/8/14 for 3/31/14   ·   Latest:  ‘10-Q’ on 5/2/24 for 3/31/24   ·   3 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/12/13  Codexis, Inc.                     10-Q        9/30/13   70:6.4M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    534K 
 2: EX-10.1     Material Contract -- exhibit101                     HTML     89K 
 3: EX-10.2     Material Contract -- exhibit102                     HTML     28K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
69: R1          Document and Entity Information                     HTML     40K 
46: R2          Condensed Consolidated Balance Sheets               HTML    129K 
43: R3          Condensed Consolidated Balance Sheets               HTML     23K 
                (Parenthetical)                                                  
16: R4          Condensed Consolidated Statements of Operations     HTML     75K 
45: R5          Condensed Consolidated Statements of Comprehensive  HTML     43K 
                Loss                                                             
31: R6          Condensed Consolidated Statements of Comprehensive  HTML     25K 
                Loss (Parenthetical)                                             
61: R7          Condensed Consolidated Statements of Cash Flows     HTML    139K 
32: R8          Description of Business                             HTML     26K 
34: R9          Basis of Presentation and Summary of Significant    HTML     80K 
                Accounting Policies                                              
17: R10         Collaborative Research and Development Agreements   HTML     39K 
33: R11         Balance Sheets Details                              HTML     49K 
60: R12         Cash Equivalents and Marketable Securities          HTML     73K 
55: R13         Fair Value Measurements                             HTML     73K 
44: R14         Related Party Transactions                          HTML     31K 
66: R15         Commitments and Contingencies                       HTML     47K 
59: R16         Warrants                                            HTML     29K 
13: R17         Stock-Based Compensation                            HTML     83K 
19: R18         Segment Reporting                                   HTML     65K 
65: R19         Restructuring                                       HTML     42K 
68: R20         Subsequent Events                                   HTML     24K 
70: R21         Basis of Presentation and Summary of Significant    HTML    106K 
                Accounting Policies (Policies)                                   
67: R22         Basis of Presentation and Summary of Significant    HTML     35K 
                Accounting Policies (Tables)                                     
49: R23         Balance Sheets Details (Tables)                     HTML     55K 
18: R24         Cash Equivalents and Marketable Securities          HTML     70K 
                (Tables)                                                         
30: R25         Fair Value Measurements (Tables)                    HTML     67K 
23: R26         Commitments and Contingencies (Tables)              HTML     33K 
22: R27         Warrants (Tables)                                   HTML     32K 
36: R28         Stock-Based Compensation (Tables)                   HTML     66K 
48: R29         Segment Reporting (Tables)                          HTML     62K 
57: R30         Restructuring (Tables)                              HTML     36K 
28: R31         Description of Business (Details)                   HTML     21K 
37: R32         Basis of Presentation and Summary of Significant    HTML     48K 
                Accounting Policies (Textual) (Details)                          
64: R33         Basis of Presentation and Summary of Significant    HTML     32K 
                Accounting Policies (Impairment of Long-Lived                    
                Assets and Intangible Assets) (Details)                          
25: R34         Basis of Presentation and Summary of Significant    HTML     31K 
                Accounting Policies (Anti-Dilutive Securities)                   
                (Details)                                                        
53: R35         Collaborative Research and Development Agreements   HTML     44K 
                (Details)                                                        
54: R36         Balance Sheets Details (Inventory) (Details)        HTML     32K 
38: R37         Balance Sheets Details (Property and Equipment)     HTML     40K 
                (Details)                                                        
21: R38         Balance Sheets Details (Accumulated Other           HTML     35K 
                Comprehensive Income (Loss)) (Details)                           
52: R39         Cash Equivalents and Marketable Securities          HTML     47K 
                (Components of Cash Equivalents and Marketable                   
                Securities) (Details)                                            
26: R40         Cash Equivalents and Marketable Securities          HTML     37K 
                (Textual) (Details)                                              
35: R41         Fair Value Measurements (Schedule of Financial      HTML     49K 
                Instruments Measured at Fair Value on Recurring                  
                Basis) (Details)                                                 
58: R42         Fair Value Measurements (Textual) (Details)         HTML     26K 
29: R43         Related Party Transactions (Details)                HTML     29K 
50: R44         Commitments and Contingencies (Textual) (Details)   HTML     43K 
42: R45         Commitments and Contingencies (Future Minimum       HTML     48K 
                Lease Payments) (Details)                                        
24: R46         Warrants (Details)                                  HTML     31K 
63: R47         Stock-Based Compensation (Textual) (Details)        HTML     57K 
20: R48         Stock-Based Compensation (Shares Available For      HTML     34K 
                Grant) (Details)                                                 
27: R49         Stock-Based Compensation (Stock-Based Compensation  HTML     36K 
                Expense) (Details)                                               
41: R50         (Revenues by Geographic Area) (Details)             HTML     32K 
47: R51         (Long-Lived Assets by Geographic Area) (Details)    HTML     27K 
62: R52         Restructuring (Changes in Restructuring Accrual)    HTML     35K 
                (Details)                                                        
14: R53         Restructuring (Textual) (Details)                   HTML     40K 
51: R54         Subsequent Events (Details)                         HTML     26K 
40: XML         IDEA XML File -- Filing Summary                      XML    102K 
15: EXCEL       IDEA Workbook of Financial Reports                  XLSX    144K 
39: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    847K 
 7: EX-101.INS  XBRL Instance -- cdxs-20130930                       XML   1.43M 
 9: EX-101.CAL  XBRL Calculations -- cdxs-20130930_cal               XML    160K 
10: EX-101.DEF  XBRL Definitions -- cdxs-20130930_def                XML    424K 
11: EX-101.LAB  XBRL Labels -- cdxs-20130930_lab                     XML   1.22M 
12: EX-101.PRE  XBRL Presentations -- cdxs-20130930_pre              XML    659K 
 8: EX-101.SCH  XBRL Schema -- cdxs-20130930                         XSD    154K 
56: ZIP         XBRL Zipped Folder -- 0001200375-13-000011-xbrl      Zip    167K

‘EX-10.2’   —   Material Contract — exhibit102

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

 <!   C:   C: 
  Exhibit 10.2  
[***] Certain information in this document has been omitted and filed separatel with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


AMENDMENT TO SUPPLY AGREEMENT

AMENDMENT TO SITAGLIPTIN CATALYST SUPPLY AGREEMENT effective as of Oct 1st 2013 (this “Amendment”) by and between Codexis, INC, (the “Vendor”), a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, CA 94063 (“CODEXIS”) and MERCK SHARPE and DOHME (the “Company”), having a place of business at One Merck Drive, Whitehouse Station, NJ 08889-0100. (“MERCK”)

W I T N E S S E T H:

WHEREAS, the parties are party to that certain SITAGLIPTIN CATALYST SUPPLY AGREEMENT dated as of February 1st 2012 as the same may have been amended to the effective date of this Amendment (as so amended, the “Agreement”); and

WHEREAS, the parties desire to amend the Agreement to modify the payment terms of the Agreement as more fully set forth below;

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:
1.
Additions and changes made to the contract in this Amendment.
1.01
Payment for amounts owed by MERCK pursuant to the Agreement shall be made by MERCK to Codexis no more than [*] ([*]) days after the date of receipt of the subject invoice. (sec# 9.1 in the Agreement)
1.02
These amended payment terms will be effective on October 1st 2013.
2.    Miscellaneous
2.01
Effect of Amendment; Joinder. Except as expressly changed by this Amendment, the Agreement shall remain in full force and effect in accordance with its stated terms. The Agreement and the Schedules and Exhibits thereto, as amended by this Amendment and all preceding amendments, set forth the entire understanding of the parties with respect to the subject matter thereof. There are no agreements, restrictions, promises, warranties, covenants or undertakings other than those expressly set forth or referred to therein. The Agreement and the Schedules and Exhibits thereto, as amended by this Amendment, supersede all prior agreements and undertakings between the parties with respect to such subject matter.
2.02
Counterparts. This Amendment may be executed by the parties in separate counterparts, each of which when so executed and delivered is deemed an original. All such counterparts together constitute but one and the same instrument.
2.03
Definitions. All capitalized terms used but not defined in this Amendment shall have the respective definitions assigned to such terms in the Agreement.
IN WITNESS WHEREOF, the parties have caused this Amendment to be signed by their duly authorized representatives as of the date and year first written above.

CODEXIS INC.
MERCK SHARPE and DOHME Corp.
 
 
 
 
By: [*]
By: [*]
Name: [*]
Name: [*]
Title: [*]
Title: [*]
Date: October 7, 2013
Date: October 13, 2013
 
 
 
 


-1-

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:11/12/138-K
10/13/13
10/7/13
For Period end:9/30/13
 List all Filings 

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/27/23  Codexis, Inc.                     10-K       12/31/22  121:15M
 2/28/22  Codexis, Inc.                     10-K       12/31/21  111:16M
 3/01/21  Codexis, Inc.                     10-K       12/31/20  110:14M
↑Top
Filing Submission 0001200375-13-000011   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 10, 4:31:05.1am ET